There have been many advancements in chemotherapy and immunotherapy treatments for various cancers over the past decade, but the 5-year relative survival rate for glioblastoma patients is still around 10%. Since glioblastoma is a rare condition, an RO-1 grant from the FDA has been awarded to GenSpera, Inc. for its research on G-202’s (mipsagargin’s) efficacy … Continue reading New Prodrug Takes Aim at Recurrent Glioblastoma